Drug Research
Affymax, Takeda launch OMONTYS injection in US
Affymax and Takeda Pharmaceutical Company have announced the availability of OMONTYS injection to treat anemia due to chronic kidney disease (CKD) in adult patients on dialysis. The once-monthly erythropoiesis-stimulating agent (ESA) for anemia is...
Drug Research
Watson introduces generic version of Fortamet
Watson Pharmaceuticals has introduced an authorized generic version of Fortamet as a part of an agreement with Shionogi. The company began the shipment of generic Fortamet (metformin hydrochloride extended-release tablets). Fortamet is indicated as an...
Drug Research
Elis Pharma to present erectile dysfunction drug Vitaros at Dubai event
Elis Pharmaceuticals will present erectile dysfunction drug Vitaros licensed from Apricus Biosciences at the Dubai International Pharmaceuticals and Technologies Conference and Exhibition (DUPHAT), as part of its pre-launch strategy. Elis Pharmaceuticals received the license...
Drug Research
EyeScience develops new eye vitamin for diabetes patients
EyeScience Labs, a resource in ocular nutrition and maker of EyeScience Macular Health Formula and EyeScience Dry Eye Formula, has developed a new eye vitamin for people with diabetes. The new product called Diabetic...
Drug Research
APP Pharmaceuticals receives marketing approval for Methotrexate Injection
APP Pharmaceuticals, a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals, has received FDA approval to market preservative-free Methotrexate Injection, USP. APP worked with the FDA to expedite approval of the oncology drug due to...
Drug Research
Ranbaxy launches cholesterol reducing drug in Australia
Ranbaxy Australia, a subsidiary of Ranbaxy Laboratories, has introduced Atorvastatin 10mg, 20mg, 40mg and 80mg tablets after receiving approval from Therapeutic Goods Administration (TGA) in Australia. The product is launched under the brand name...
Drug Research
La Jolla buys GCS-100 rights from Solana
La Jolla Pharmaceutical Company has acquired global development and commercialization rights to GCS-100 from Solana Therapeutics. GCS-100 is an inhibitor of galectin-3, a novel molecular target implicated in cancer and chronic organ failure. Galectin-3 plays...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
